Inhibikase Therapeutics (IKT) Stock Analysis: AI Score & Alternative Data
IKT alt-data: headcount climbing, web traffic lagging
Is Inhibikase Therapeutics a buy right now? The alternative data says hold. This IKT stock analysis is built on the 25+ alternative data signals AltIndex tracks on Inhibikase Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 47/100: a Hold. The stock trades at $1.82 with a $275M market cap.
The bullish side of the 90-day ledger: headcount (according to LinkedIn) up 22.6% to 38 employees. The drag: web traffic down 37.5% to 2K monthly visits. That tension is what keeps the score mid-range.
IKT’s broader alt-data profile also covers sentiment (100/100). Every signal links to its own page with full history, the IKT technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on IKT is just below.
Inhibikase Therapeutics AI Stock Analysis
Founded with a mission to develop innovative solutions for critical health challenges, Inhibikase Therapeutics focuses on the discovery, development, and commercialization of therapies for diseases like Parkinson’s and multiple system atrophy.
Analysis generated October 9, 2026.
Recent Inhibikase Therapeutics Stock Alerts
|
Inhibikase Therapeutics | October 12 Price is down by -6.1% in the last 24h. |
|
Inhibikase Therapeutics | October 1 Price is down by -6.1% in the last 24h. |
|
Inhibikase Therapeutics | September 23 Price is down by -6.1% in the last 24h. |
|
Inhibikase Therapeutics | September 2 Price is up by 6.3% in the last 24h. |
Inhibikase Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 2K | 37.5% | |
| Job Posts | 0 | 100.0% | |
| LinkedIn Employees | 38 | 22.6% | |
| Employee Recommend | 0 | N/A | |
| Business Outlook | 0 | N/A | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | 100.0% | |
| X Mentions | 1 | 50.0% | |
| Stocktwits Mentions | 1 | 0% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 2K | 0% | |
| 4chan Mentions | 0 | N/A |
About Inhibikase Therapeutics (IKT)
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside and outside the brain. The company is headquartered in Atlanta, Georgia.
| Price | $1.82 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $275M |
| Year Range | $1 – $3 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Inhibikase Therapeutics News
View more →
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2 - GlobeNewswire |
|
 |
Parkinson's Disease Market Poised for Expansion During the Forecast Period (2026-2036) Amid JUVMO Approval and Emerging Therapeutic Innovations | DelveInsightOctober 6 - PRNewswire |
 |
Pulmonary Arterial Hypertension Market Outlook Shows Strong Upward Trend at a CAGR of 6.7% During the Study Period (2022-2036) Supported by New Clinical Developments | DelveInsightMay 25 - PRNewswire |
Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightMay 19 - GlobeNewswire |
See Inhibikase Therapeutics’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for IKT, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEInhibikase Therapeutics Earnings & Financial Performance
View all earnings →Inhibikase Therapeutics Insider Trading Activity
View all →| Sands Capital Alternatives, LLC filed to sell 13,018,965 shares at $0.0. Nov 21 '25 |
| Munshi Amit filed to sell 365,000 shares at $0.0. Oct 21 '24 |
| Kush Arvind filed to sell 145,000 shares at $0.0. Oct 21 '24 |
| Bellini Roberto filed to sell 1,460,000 shares at $0.0. Oct 21 '24 |
| Werner Milton H. filed to sell 5,335,433 shares at $0.0. Aug 16 '22 |
Inhibikase Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Inhibikase Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Vanda PharmaceuticalsVNDA |
$4.52 1.1% | $276M | 47 |
 |
Larimar TherapeuticsLRMR |
$2.63 1.5% | $277M | 49 |
 |
Palisade BioPALI |
$1.59 3.3% | $268M | 48 |
 |
Abeona TherapeuticsABEO |
$4.91 0.7% | $282M | 48 |
 |
Century TherapeuticsIPSC |
$1.45 1.7% | $266M | 49 |
Explore Inhibikase Therapeutics Data
Frequently Asked Questions: Inhibikase Therapeutics (IKT)
Inhibikase Therapeutics has an AltIndex AI Score of 47/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
47/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Inhibikase Therapeutics (IKT) stock is $1.82 with a market cap of $275M.
As of today, Inhibikase Therapeutics’s PE (Price to Earnings) ratio is —.
View the latest Inhibikase Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Inhibikase Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The IKT stock price chart above shows Inhibikase Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Inhibikase Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Inhibikase Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
